QurCan Therapeutics Inc.
Toronto
About QurCan Therapeutics Inc.
Nanology Labs has designed and is developing Manganescan®, a novel theranostic agent (MRI contrast agent/Radio-sensitizer) that allows detection of brain tumors at early stages using MRI. Simultaneously, it sensitizes cancer cells which improves radiation therapy outcomes. The agent is 3x more sensitive than current Gadolinium contrast agents (GBCAs), can cross the blood brain barrier and enables early and precise detection and targeting of brain cancer.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $3.0M
- Funding stage: Seed
- Last round: Seed (May 2021)
- Website: qurcan.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Life Science, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/qurcan-therapeutics-inc-12502 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.